MiRNA Firm Firefly BioWorks Raises $2M | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – MicroRNA-based technology startup Firefly BioWorks has raised about $2 million in a private financing, which it plans to use to test its platform directed at cancer-related research.

Firefly co-founder and CEO Davide Marini, told GenomeWeb Daily News that the company plans to test the product with a select group of researchers to assess its utility but declined to provide further details. He also declined to identify investors in the round.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.